Rockin' HIT Sales Podcast

Podcast / Sam Morhaim


Why Clinical AI Dies in Pilot: From Impressive Demo to Hospital-Ready System


Sam Morhaim, CEO of Vantage AI explains why clinical AI pilots fail, what provider facility reviewers expect, and how HealthTech teams can move from impressive demo to hospital-ready system.

Release Date:

Hosted by David Hacker, CPHIMS | Director, Elevate HIT Sales | MEDDPICC® Certified Trainer

Watch or Listen

Choose your preferred platform:

Also available on all major podcast platforms.

Episode Summary

In this episode of Rockin’ HIT Sales, David Hacker sits down with Sam Morhaim, CEO of Vantage IO, for a practical conversation on why clinical AI pilots often fail after a strong demo.

Sam explains why the problem is usually not the model alone. The breakdown often happens in the surrounding architecture: evidence grounding, traceability, audit trails, failure handling, PHI data flow, compliance, workflow fit, and the ability to safely handle edge cases.

The discussion also gets into one of the most important emerging issues in healthcare AI: RAG. Sam breaks down why retrieval-augmented generation can create new risks around PHI leakage, data exposure, patient-level separation, and evidence grounding if teams do not design it carefully from the start.

For HealthTech founders, CTOs, product leaders, GTM teams, and investors, this episode is a clear look at what separates an impressive AI demo from a clinical-grade system that can survive hospital review, earn trust, and move toward real deployment.

Why This Matters for Health IT Companies

A strong clinical AI demo does not prove that a solution is ready for a hospital environment. Provider review goes beyond model performance to questions about evidence grounding, traceability, PHI movement, auditability, failure handling, security, workflow fit, and what happens when the system encounters circumstances the development team did not anticipate.

For AI-enabled Health IT companies, that makes technical architecture part of go-to-market readiness. Vendors need to be able to explain not only what their AI produces, but where its information comes from, where patient data lives and flows, how uncertainty is handled, how outputs can be reconstructed, and what safeguards are in place before asking a health system to trust the solution in a clinical environment.

What You’ll Hear in This Episode

  • Why clinical AI pilots often fail after a strong demo
  • What separates “works on GPT” from “hospital-ready”
  • Why model accuracy alone is not enough to establish trust
  • How RAG can create evidence, PHI, and data-governance risks
  • What hospital reviewers look for around traceability, auditability, and failure handling
  • Why clinical AI teams should stop claiming “hallucination-free” AI
  • How architecture has become part of go-to-market readiness for clinical AI

Questions This Episode Answers

Why do clinical AI pilots fail even when the original demo performs well?

The problem is often not the model itself. Failures frequently occur in the surrounding system—evidence grounding, audit trails, failure handling, edge cases, data movement, and other safeguards that were not fully addressed in the controlled development environment.

What separates an impressive AI prototype from a hospital-ready clinical system?

A production system needs layers that a prototype may not have: secure architecture, traceability, logging, evidence grounding, safe failure behavior, compliance controls, and the ability to operate reliably when real-world workflows and unexpected cases replace the clean conditions of a demo.

Is model accuracy enough to make clinical AI trustworthy?

No. A clinical AI system also needs to recognize uncertainty, identify weak evidence, trace answers back to their sources, and provide enough auditability to reconstruct how an output was produced. Sam identifies those capabilities as important differences between a prototype and a production-ready system.

Why can retrieval-augmented generation create additional risk in healthcare AI?

RAG introduces another layer through which sensitive information is indexed, retrieved, and exposed. Poorly designed separation or retrieval can create PHI leakage and even the possibility of information from different patients being exposed inappropriately.

What should an AI company have ready before entering a health system review process?

At minimum, the company should be able to clearly map where PHI lives, where it travels, how it is stored, which systems or models receive it, and what safeguards govern that movement. That information helps address many of the security, privacy, and technical questions a provider will raise.

How should AI companies talk about hallucinations and system limitations?

They should avoid absolute claims such as “hallucination-free.” AI systems are non-deterministic, and credibility comes from being transparent about uncertainty, testing for unexpected conditions, and demonstrating how the system detects and handles situations where confidence is low.

Why has technical architecture become part of go-to-market readiness for clinical AI?

Because provider buyers increasingly need evidence that what a vendor claims about its system is actually supported by the way the system is built. Architecture, data flows, transparency, safeguards, and observability can therefore influence trust, differentiation, procurement, and whether an AI solution progresses beyond a pilot.

David’s GTM Takeaways for Clinical AI Companies

1. Architecture is now part of the sales conversation. Clinical AI vendors cannot separate technical readiness from commercial readiness. If a sales team cannot explain where data flows, how evidence is grounded, how outputs are traced, and what happens when the system is uncertain, provider due diligence can expose that weakness quickly.

2. Trust requires evidence that can be followed backward. “Accurate” is not enough. Health systems need confidence that an AI result can be traced to its sources, reconstructed when necessary, and challenged when the underlying evidence is weak. Traceability and auditability should therefore become part of the vendor’s value and trust story.

3. Don't create credibility problems by overclaiming. Claims such as “hallucination-free” may sound powerful in a sales presentation but can have the opposite effect with sophisticated reviewers. A stronger position is to acknowledge uncertainty and demonstrate the safeguards, monitoring, testing, and failure modes designed to manage it.

Sam’s discussion on why clinical AI pilots fail connects directly to the need for HealthTech teams to pressure-test their AI readiness before provider review.

Download the AI Risk Self-Assessment Toolkit

About the Guest

Sam Morhaim is the Founder and CEO of Vantage IO, where he leads a senior engineering team focused on healthcare AI architecture, HIPAA-aware system design, PHI data-flow mapping, and building software systems that can survive real-world healthcare review and scale. Vantage IO positions its work around helping healthcare teams fix fragile AI systems, design new ones correctly, and reduce risk before enterprise deployment.

In this episode of Rockin’ HIT Sales, Sam brings the builder’s perspective on why clinical AI pilots often fail after a strong demo. His work focuses on the gap between “works on GPT” and “hospital-ready” systems — including evidence grounding, explainability, security review, compliance, workflow fit, and fail-safe behavior. His perspective is especially relevant for HealthTech founders, CTOs, product leaders, and GTM teams trying to understand what must be true before clinical AI can earn trust inside provider organizations.

Transcript

Prefer to read or download the conversation?

Download Transcript

← Back to all podcast episodes